Mitsubishi UFJ Trust & Banking Corp decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.2% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,499,899 shares of the biopharmaceutical company’s stock after selling 18,449 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Gilead Sciences were worth $102,808,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Sawyer & Company Inc purchased a new stake in Gilead Sciences in the 2nd quarter valued at about $28,000. Meridian Wealth Partners LLC purchased a new stake in Gilead Sciences in the 1st quarter valued at about $32,000. Elmwood Wealth Management Inc. purchased a new stake in Gilead Sciences in the 1st quarter valued at about $35,000. Burleson & Company LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth about $43,000. Finally, Lumature Wealth Partners LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter worth about $51,000. Institutional investors own 78.04% of the company’s stock.
A number of brokerages have recently issued reports on GILD. Morgan Stanley reiterated a “buy” rating and set a $83.00 target price on shares of Gilead Sciences in a report on Friday, August 27th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 target price for the company in a report on Tuesday, August 10th. Royal Bank of Canada reiterated a “buy” rating and set a C$84.00 target price on shares of Gilead Sciences in a report on Monday, August 23rd. SVB Leerink boosted their target price on Gilead Sciences from $74.00 to $77.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Finally, Oppenheimer assumed coverage on Gilead Sciences in a report on Monday, June 28th. They issued a “buy” rating and a $100.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $105.67.
Shares of NASDAQ:GILD traded up $0.69 on Tuesday, hitting $71.65. The company’s stock had a trading volume of 200,080 shares, compared to its average volume of 7,361,570. Gilead Sciences, Inc. has a 12 month low of $56.56 and a 12 month high of $73.34. The company has a market capitalization of $89.84 billion, a price-to-earnings ratio of 17.47, a price-to-earnings-growth ratio of 0.63 and a beta of 0.39. The stock’s 50-day moving average is $70.44 and its two-hundred day moving average is $67.83. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.19 and a current ratio of 1.36.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.76 by $0.11. The business had revenue of $6.22 billion during the quarter, compared to the consensus estimate of $6.15 billion. Gilead Sciences had a return on equity of 55.94% and a net margin of 19.38%. During the same period in the prior year, the business posted $1.11 earnings per share. Equities analysts expect that Gilead Sciences, Inc. will post 7.15 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 29th. Stockholders of record on Wednesday, September 15th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date of this dividend is Tuesday, September 14th. Gilead Sciences’s dividend payout ratio is 40.06%.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Article: What factors cause inflation to rise?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.